Provides an updated overview of Carney complex, including its clinical features, diagnosis, treatment, and molecular etiology involving PKA subunit defects.
Answers are grounded in this paper and cite their sources.
Aids recognition of Carney complex among cardiac myxoma patients; leaves open targeted therapies for PRKAR1A/PRKACA defects.
Carney complex (CNC) is a rare autosomal dominant syndrome, characterized by pigmented lesions of the skin and mucosa, cardiac, cutaneous and other myxomas and multiple endocrine tumors. The disease is caused by inactivating mutations or large deletions of the PRKAR1A gene located at 17q22-24 coding for the regulatory subunit type I alpha of protein kinase A (PKA) gene. Most recently, components of the complex have been associated with defects of other PKA subunits, such as the catalytic subunits PRKACA (adrenal hyperplasia) and PRKACB (pigmented spots, myxomas, pituitary adenomas). In this report, we review CNC, its clinical features, diagnosis, treatment and molecular etiology, including PRKAR1A mutations and the newest on PRKACA and PRKACB defects especially as they pertain to adrenal tumors and Cushing's syndrome.
No takes yet. Share an insight, caveat, or question.
Correa et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: